Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies-Reference-Cited by-同舟云学术

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Published:2017-12-23 Issue:3 Volume:93 Page:401-407
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

DiNardo Courtney D.¹^ORCID,Rausch Caitlin R.²^ORCID,Benton Christopher¹,Kadia Tapan¹^ORCID,Jain Nitin¹,Pemmaraju Naveen¹^ORCID,Daver Naval¹^ORCID,Covert Wendy²,Marx Kayleigh R.²,Mace Morgan²,Jabbour Elias¹^ORCID,Cortes Jorge¹,Garcia-Manero Guillermo¹,Ravandi Farhad¹,Bhalla Kapil N.¹,Kantarjian Hagop¹^ORCID,Konopleva Marina¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Pharmacy; The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

University of Texas MD Anderson Cancer Center

Charif Souki Cancer Research Fund

MD Anderson Cancer Center Leukemia SPORE

Publisher

Wiley

Subject

Hematology

Reference28 articles.